TOCILIZUMAB TREATING COVID PNEUMONIA: ANALYSIS OF EFFECTIVENESS AND SECURITY

C. DEL POZO CARLAVILLA¹, M. CLEMENTE ANDÚJAR¹, S. PLATA PANIAGUA¹, M. DEL POZO CARLAVILLA², S RUIZ SÁNCHEZ¹, B. SERNA SERRANO¹, C.S. JUAN MANUEL¹, E. TEBAR MARTÍNEZ¹, H. ALABORT AYLÓN³, M. SÁEZ GARRIDO¹. ¹COMPLEJO HOSPITALARIO DE ALBACETE, HOSPITAL PHARMACY, ALBACETE, SPAIN. ²COMPLEJO HOSPITALARIO DE ALBACETE, PAEDIATRICS, ALBACETE, SPAIN.

OBJECTIVE
The main objective is to evaluate TCZ security and effectiveness in the treatment of COVID-19 pneumonia.

MATERIALS AND METHODS
Retrospective observational study among patients with COVID-19 pneumonia treated with TCZ from 20th March to 20th May 2020 at a tertiary hospital.

RESULTS

72 hours after TCZ administration 52.5% of the patients presented a respiratory improvement with an oxygen therapy reduction need, 30.5% (presented a stabilization in their condition and 8.5% suffered a worsening in the condition, requiring orotracheal intubation.

7 days after TCZ administration 73% presented a clinical improvement with an oxygen therapy need reduction, 8.5% patients remained stable with VNI and 14% suffered a worsening. (6 passed out, 2 were admitted at the ICU).

TCZ dosage was 600 mg in 43 (72.9) patients and 400 mg in 16 (27.1%) patients, with 1,27 doses per patient. 12 patients received 2 doses and 2 patients 3 doses. Tocilizumab was well tolerated with no adverse effects detected.

28 days after TCZ administration, mortality was 15.2%, 69% were discharged and 15.2% remained interned at the end of the study.

CONCLUSIONS
Results of the study show TCZ was effective and safe at patients suffering from COVID pneumonia. Patients evolution was favourable in most of the cases. During admission, patients presented an important clinical improvement with a reduction of invasive ventilation and oxygen therapy need.

Due to a potential bias (patients received different treatments before and after TCZ) and the small sample size, it is necessary to confirm these results with controlled clinical essays.